Back to 2024 Posters
Dermabond for Reduction Mammoplasty Revisited: Its Effects on Postoperative Wound Healing
Stephanie Francalancia, MS, Mary Lou, BS, Damon McIntire, MD, Nikhil Sobti, MD, Navya Baranwal, BA, Elijah Persad-Paisley, BA, Jesse Menville, BA, Brooke Barrow, MD, Josue Marquez, BS, Paul Liu, MD, Rachel Sullivan, MD
Brown University Warren Alpert Medical School, Providence, RI, USA
PURPOSE: Wound dressing following reduction mammoplasty can be conducted using surface 2-Octyl cyanoacrylate (Dermabond; Ethicon, Inc., Somerville, N.J), but its effect on long-term wound healing in these patients is inconclusive. We present an updated review of Dermabond’s safety and efficacy in reduction mammoplasty patients.
METHODS:A retrospective analysis was conducted on 550 patients who underwent reduction mammoplasty by a single surgeon between March 2015 and February 2023. Demographic, operative time, and postoperative complication data were collected from patient records and summarized with descriptive statistics. Patients were separated into Dermabond and non-Dermabond dressing groups. Student’s t-test for continuous variables and Fisher’s exact test for categorical variables were used to evaluate differences in demographics and postoperative outcomes between groups. A random sample of 200 from the non-Dermabond group (non-Dermabond cohort) was used to generate a one-to-one matched Dermabond cohort of 200 patients without significant differences in baseline demographics.
RESULTS: Out of 550 patients, 278 (50.5%) had Dermabond used and 272 (49.5%) did not. After cohort matching, rates of seromas (p<0.001), dehiscence (p<0.001), and hypertrophic scarring (p=0.030) were significantly higher in the Dermabond cohort. There were statistically similar rates of hematoma, infection, nipple insensitivity, and fat necrosis between the cohorts (Figure 1).
CONCLUSION: Dermabond’s use as wound dressing after reduction mammoplasty was associated with higher rates of seromas, dehiscence, and scarring, suggesting a negative impact on postoperative outcomes.
Back to 2024 Posters
